Zydus Cadila to launch two more novel drugs by 2020
The drug firm plans to launch at least two molecules out of 20 under discover research programmes by 2020.
New Delhi, June 10, 2013: Buoyed by the approval of its patented drug, Lipaglyn, Zydus Cadila plans to launch at least two molecules out of the 20 currently under discovery research programmes to become successful by 2020. It may be noted here that the company has set out on a path to become a research-driven pharmaceutical company by 2020 and is currently working in the areas of metabolic disorders, oncology and inflammatory disorders.
The company currently spends over seven per cent of its turnover on R&D and plans to continue to do so going forward. The company plans to raise the funds for the drug discovery programmes from internal resources.
The company expects the drug to be blockbuster and clock over US$ 1 billion in sales a year when it will be sold globally. The company plans to launch the drug in India in the third quarter of this fiscal.